GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » EBITDA Margin %

Astellas Pharma (Astellas Pharma) EBITDA Margin % : 15.91% (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Astellas Pharma's EBITDA for the three months ended in Dec. 2023 was $466 Mil. Astellas Pharma's Revenue for the three months ended in Dec. 2023 was $2,930 Mil. Therefore, Astellas Pharma's EBITDA margin for the quarter that ended in Dec. 2023 was 15.91%.


Astellas Pharma EBITDA Margin % Historical Data

The historical data trend for Astellas Pharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma EBITDA Margin % Chart

Astellas Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.02 24.20 17.63 18.63 16.26

Astellas Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.27 -6.43 19.42 11.87 15.91

Competitive Comparison of Astellas Pharma's EBITDA Margin %

For the Drug Manufacturers - General subindustry, Astellas Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's EBITDA Margin % falls into.



Astellas Pharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Astellas Pharma's EBITDA Margin % for the fiscal year that ended in Mar. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2023 )/Revenue (A: Mar. 2023 )
=1847/11361.441
=16.26 %

Astellas Pharma's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=466.22/2930.46
=15.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Astellas Pharma  (OTCPK:ALPMY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Astellas Pharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma (Astellas Pharma) Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products across the globe. The vast majority of the company's revenue is derived from Japanese markets, followed by the Americas. Royalty income makes up a small percentage of Astellas' overall sales. Its largest therapeutic area by sales composition is oncology, followed by urology and transplantation. The company uses mergers and acquisitions as part of its long-term growth strategy. Astellas enters into strategic partnerships and licensing agreements to strengthen its commercialization platforms.